From: Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease
Prior treatments / interventions | N (%) |
---|---|
Surgery / intervention | |
Thoracoscopy +/− intervention | 53 (32%) |
No surgery / intervention | 37 (23%) |
Cardiothoracic surgery | 31 (19%) |
Other intervention | 11 (7%) |
Unknown surgery / intervention | 32 (20%) |
First line anticancer treatment (n = 164) | |
Platinum + pemetrexed | 117 (71%) |
Clinical trial | 21 (13%) |
MVP (mitomycin C, vinblastine, cisplatin) | 15 (9%) |
Other chemotherapy regimen | 6 (4%) |
Incomplete / missing information | 5 (3%) |
Second line anticancer treatment (n = 117, 71%) | |
Clinical trial | 58 (50%) |
Rechallenge platinum and pemetrexed | 27 (23%) |
Other chemotherapy regimen | 26 (22%) |
Incomplete / missing information | 6 (5%) |
Median total treatments prior to referral | 2 (range 0–6) |